Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-block Randomized, Double-blind, Placebo/Active-controlled, Single/Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics of SA001 After Oral Administration in Healthy Male Subjects

NCT05303961 is registered in ClinicalTrials.gov with Samjin Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05303961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05303961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-block Randomized, Double-blind, Placebo/Active-controlled, Single/Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics of SA001 After Oral Administration in Healthy Male Subjects
Lead sponsor
Samjin Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 7, 2016
Completion date
November 11, 2016
Enrollment
56 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy